Background and objective Amyloid-positron emission tomography (PET) imaging (API) detects amyloid-beta pathology early in the course of Alzheimer’s disease (AD) with high sensitivity and specificity. (18)F-florbetapir (Amyvid) is an amyloid-binding PET ligand with a half-life suitable for clinical use outside of the research setting. How API affects patient investigation and management in the ‘real-world’ arena is unknown. To address this, we retrospectively documented the effect of API in patients in the memory clinic.
Methods We reviewed the presenting clinical features, the pre-API and post-API investigations, diagnosis and outcomes for the first 100 patients who had API as part of their routine work-up at the Imperial Memory Centre, a tertiary referral clinic in the UK National Health Service.
Results API was primarily used to investigate patients with atypical clinical features (56 cases) or those that were young at onset (42 cases). MRI features of AD did not always predict positive API (67%), and 6 of 23 patients with MRIs reported as normal were amyloid-PET positive. There were significantly more cases categorised as non-AD dementia post-API (from 11 to 23). Patients investigated when API was initially available had fewer overall investigations and all patients had significantly fewer investigations in total post-API.
Conclusions API has a clear impact on the investigation of young-onset or complex dementia while reducing the overall burden of investigations. It was most useful in younger patients, atypical presentations or individuals with multiple possible causes of cognitive impairment.
- image analysis
- pet, functional imaging
Statistics from Altmetric.com
PAM and RJP are joint senior authors.
Contributors The study was designed by RP, PAM and AW, the data were acquired and presented by CJC, KM, RK, TB, AK, AW, ZW, the data was interpreted by CJC, PM and RP, figures were created by CJC, the paper was written and revised by CJC, KM, RK, AK, PAM, GD, TB, ZW and RP.
Funding The patients were investigated within their treatment in the NHS. No specific external funding was acquired. This work was supported by the NIHR Biomedical Research Centre at Imperial College London.
Competing interests RP has worked in an advisory role for Roche, Eli Lilly, Merck, and GE. PM has a ‘drugs-only’ grant from Shire Pharmaceuticals and research funding from the UK National Institute of Health Research and Medical Research Council.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement We will consider sharing our data on request.
Correction notice This article has been corrected since it was published Online First. The joint senior author statement has been included.